{"url_path":"/sec/btai/8-k/2026-07-06/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-06","source_url":"https://www.sec.gov/Archives/edgar/data/1720893/0001104659-26-080501-index.html","accession_number":"0001104659-26-080501","cik":"0001720893","ticker":"BTAI","issuer_name":"BioXcel Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1720893/0001104659-26-080501-index.html","primary_entity_key":"0001720893","primary_entity_name":"BioXcel Therapeutics, Inc."},"word_count":305,"has_tables":true,"body_markdown":"false\n0001720893\n\n0001720893\n\n2026-07-06\n2026-07-06\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n** **\n\n \n\n** **\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of\nthe**\n\n**Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):\nJuly 6, 2026**\n\n \n\n \n\n**BioXcel\nTherapeutics, Inc.**\n\n**(Exact name of registrant as specified in its\ncharter)**\n\n \n\n \n\n**Delaware**\n \n**001-38410**\n \n**82-1386754**\n\n**(State\nor other jurisdiction of\nincorporation)**\n \n**(Commission\nFile Number)**\n \n**(I.R.S.\nEmployer Identification No.)**\n\n \n\n**555\nLong Wharf Drive**\n\n**New\nHaven****, CT****06511**\n\n**(Address of principal executive offices, including\nZip Code)**\n\n \n\n**(475****)\n238-6837**\n\n**(Registrant’s telephone number, including\narea code**)\n\n \n\n**N/A**\n\n**(Former name or former address, if changed\nsince last report)**\n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:\n\n \n\n¨Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\n**Securities registered\npursuant to Section 12(b) of the Act:**\n\n \n\n**Title of each class**\n** **\n**Trading Symbol(s)**\n** **\n**Name of each exchange on which ****registered**\n\nCommon\nStock, par value $0.001\n \nBTAI\n \nThe Nasdaq\nCapital Market\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ¨\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨"}